Cargando…
Effectiveness of Canakinumab Treatment in Colchicine Resistant Familial Mediterranean Fever Cases
Anti-interleukin 1 agents are used successfully in colchicine-resistant or intolerant Familial Mediterranean Fever (FMF) patients. Sixty-five patients with FMF who received canakinumab treatment for at least 6 months due to colchicine resistance or intolerance between 2016 and 2020 in our department...
Autores principales: | Yücel, Burcu Bozkaya, Aydog, Ozlem, Nalcacioglu, Hulya, Yılmaz, Ayşegül |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8461313/ https://www.ncbi.nlm.nih.gov/pubmed/34568239 http://dx.doi.org/10.3389/fped.2021.710501 |
Ejemplares similares
-
Case report: Thrombotic microangiopathy in pediatric multisystem inflammatory syndrome associated with COVID-19: a case series
por: Nalçacıoğlu, Hülya, et al.
Publicado: (2023) -
Feasibility of canakinumab withdrawal in colchicine-resistant familial Mediterranean fever
por: Sener, Seher, et al.
Publicado: (2023) -
Treatment of familial mediterranean fever with canakinumab in patients who are unresponsive to colchicine
por: Berdeli, Afig, et al.
Publicado: (2019) -
Efficacy and safety of canakinumab in adolescents and adults with colchicine-resistant familial Mediterranean fever
por: Gül, Ahmet, et al.
Publicado: (2015) -
Endocan: A Novel Marker for Colchicine Resistance in Familial Mediterranean Fever Patients?
por: Omma, Ahmet, et al.
Publicado: (2021)